View Solutions for COPD and Bronchiectasis (BE) Patients, airing on PBS View PBS Video

Bronchiectasis resources for practitioners

Sometimes when you see COPD, chronic bronchitis, pneumonia, asthma or cystic fibrosis, you might also see bronchiectasis (BE)—a condition where the lungs’ airways are abnormally stretched and scarred resulting in mucus retention. It’s an under-diagnosed disease demanding action—and your attention.

Is it COPD—or BE?

A CT scan can help determine a diagnosis of BE. Early diagnosis and intervention is the key to slowing the disease progression and helping your patients live better with BE.

Relatively common, especially as people age

BE can frequently occur in parallel with more common forms of chronic lung disease.

A recent study presented at CHEST 2016 Annual meeting demonstrated a prevalence of BE in moderate to severe COPD patients. 8


The same study showed that 92.7% of those COPD patients that had ≥ 2 exacerbations or at least 1 hospitalization per year had BE.8

Is your patient a candidate for diagnostic screening for BE?

Products for airway clearance

Although there is no cure for bronchiectasis (BE), early detection and treatment will allow patients to have a better quality of life and prevent further lung damage. Along with antibiotics and other appropriate medications, airway clearance therapies provide an effective, safe treatment. One category of airway clearance therapy is referred to as high frequency chest wall oscillation (HFCWO), also known as “vest therapy.”



How does high frequency chest wall oscillation (HFCWO) work?

HFCWO devices effectively treat all areas of your lungs by creating oscillating airflows that move mucus upward where it is easier to cough out. Keeping mucus from building up in your lungs helps to reduce the frequency of infection and hospitalizations, helps prevent further damage to your lungs and, best of all, helps you feel better. These airway clearance devices do not require special skills or techniques to administer quality airway clearance therapy—most patients are able to use them on their own. The system rapidly oscillates against the chest, gently compressing and releasing the chest wall, creating increased airflow within the lungs. This process thins and moves mucus toward the larger airways where it can be cleared by coughing or suctioning.



Airway Clearance

Connected in care

Some airway clearance devices now include wireless transmission of therapy sessions, providing you with prompt patient treatment feedback via an easy-to-use portal. With both the patient and the healthcare team having access to the portal, it helps patients stay motivated with their therapy and allows the healthcare team to see usage information and trends over time. This technology allows you to have the most accurate data at your fingertips and enables you to have informed conversations with your patient regarding their airway clearance treatments.



Mobile Battery-Operated HFCWO

Another HFCWO device option is a mobile, battery-operated vest device that provides patients with HFCWO therapy without the need to be plugged into an electrical outlet.  Like other HFCWO devices, this device rapidly oscillates against the chest wall to generate air pulses within the lung. The therapy generates airflow to help thin and move mucus from the airways, while allowing you to move about freely while doing your therapy.



Medicare Coverage Criteria for HFCWO


Patient diagnosed with bronchiectasis:

Confirmed by a standard CT scan, which is characterized by:

a) Daily productive cough for at least six continuous months;


b) Frequent (i.e. three or more in a year) exacerbations requiring antibiotic therapy;


There must be well-documented failure of standard treatments to adequately mobilize retained secretions.

Examples of standard treatments:

  • Manual Chest Percussion Therapy (CPT)
  • Postural drainage
  • Positive Expiratory Pressure (PEP) device
  • Nebulized medication with mucolytic

Additional Resources

For more information on Hill-Rom’s airway clearance therapies, visit Hill-Rom’s website.

  1. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:400–7.
  2. Garcia, M, et al. Prognostic Value of Bronchiectasis in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2013;187:823-8.
  3. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12:205–9.
  4. Martínez-García MÁ1, Soler-Cataluña JJ, Donat Sanz Y, Catalán Serra P, Agramunt Lerma M, Ballestín Vicente J, Perpiñá-Tordera M. Factors associated with bronchiectasis in patients with COPD. Chest. 2011 Nov;140(5):1130-7. doi: 10.1378/chest.10-1758. Epub 2011 May 5.
  5. Maguire G. Bronchiectasis–A guide for primary care. Australian Family Physicians Vol 41. No. 11 November 2012.
  6. Barker AF. Bronchiectasis. N Engl J. Med 2002; 346: 1383-1393.
  7. American Thoracic Society. accessed 10-20-16.
  8. Kosmas E, Dumitru S, Gkatzias S, et al. Bronchiectasis in patients with COPD: an irrelevant imaging finding or a clinically important phenotype? American College of Chest Physicians. Elsevier Inc., 2016. doi:
©2018 Hill-Rom Services PTE Ltd. ALL RIGHTS RESERVED.
206963 rev 1 25-OCT-2017 ENG – US